Jardine Matheson share price edges lower as buybacks roll on, MAS decision next
26 January 2026
1 min read

Jardine Matheson share price edges lower as buybacks roll on, MAS decision next

SINGAPORE, Jan 26, 2026, 15:42 SGT — Regular session

  • Jardine Matheson’s shares slipped roughly 0.1%, landing at US$74.71 in afternoon trading.
  • A recent filing revealed another share buyback, with purchases made near the current market price.
  • Traders are focused on Singapore’s central bank review set for Jan 29, along with the group’s March earnings release.

Jardine Matheson Holdings Limited shares slipped 0.1% to US$74.71 by mid-afternoon in Singapore on Monday. The stock fluctuated between US$74.53 and US$75.00, holding near its recent high of US$75.80. 1

The pullback may be minor, but its timing is crucial. As the stock hovers near its highs, traders search for any sign that can stabilize the price — buybacks stand out as one of the rare consistent signals investors rely on between earnings and major corporate actions.

A filing with the UK’s Financial Conduct Authority revealed Jardine bought back 112,700 shares on Jan. 23 at a weighted average price of US$74.7147, with plans to cancel them. At the disclosure date, the company reported holding 295,293,978 ordinary shares carrying voting rights. 2

SGX market strategist Geoff Howie noted in a Sunday report that Jardine repurchased 270,300 shares from Jan. 16 to 22, paying an average of US$74.57 each. The group has announced a buyback plan capped at US$250 million and is set to release its FY2025 results in March. 3

The broader market slipped. Singapore’s Straits Times Index fell 0.5% to 4,866, pulling back from last week’s peaks as investors shifted away from a few top performers. 4

Macro factors have returned to focus. Singapore is widely expected to hold its monetary policy steady at Thursday’s review, with 15 out of 16 economists surveyed by Reuters predicting no change. Tay Qi Hang, an analyst at Economist Intelligence Unit Asia, noted that “growth outperformance… has reduced near-term pressure to ease.” 5

Buybacks can only do so much. Jardine’s performance depends on a diverse set of businesses—Hongkong Land, Dairy Farm, Mandarin Oriental, Jardine Cycle & Carriage, and Astra—and fluctuations in property, consumer spending, or regional growth often overshadow any boost from a reduced share count. 6

The group is incorporated in Bermuda and holds its main listing on the London Stock Exchange, alongside secondary listings in Bermuda and Singapore, the company states. This setup broadens its investor base but also means sentiment can swing quickly across different time zones. 7

What’s next is clearer. Traders are set to focus on the Monetary Authority of Singapore’s policy statement and forecast update on Thursday, Jan. 29. They’ll also keep an eye out for any new buyback announcements from Jardine as the week progresses. 8

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
iFAST stock rises near a 52-week high — the MAS decision and Feb. results are the next triggers
Previous Story

iFAST stock rises near a 52-week high — the MAS decision and Feb. results are the next triggers

Rolls-Royce share price today: what to watch before London opens for RR.L
Next Story

Rolls-Royce share price today: what to watch before London opens for RR.L

Go toTop